Effects of the serotonergic anxiolytic buspirone on plasma glucose and glucose-induced hyperglycemia in mice.

Abstract

Effects of the serotonergic anxiolytic buspirone on plasma glucose and glucose-induced hyperglycemia were studied in mice. Buspirone did not affect plasma glucose levels of non-fasted mice, while it increased serum insulin levels. In fasted mice, buspirone significantly reduced glucose-induced hyperglycemia and enhanced insulin release elicited by glucose. This suggests that buspirone enhances insulin release, resulting in inhibition of glucose-induced hyperglycemia. The major metabolite of buspirone, 1-(2-pyrimidinyl)piperazine (1-PP) increased serum insulin levels and induced a slight hypoglycemia in non-fasted mice. 1-PP decreases glucose-induced hyperglycemia and amplifies insulin release elicited by glucose in fasted mice. Since buspirone is mainly metabolized to 1-PP and formation of 1-PP occurs quickly, the inhibitory effect of buspirone on glucose-induced hyperglycemia is likely mediated by 1-PP.

• Authors: Yumi Sugimoto, Nozomu Takashima, Toshiko Noma, Jun Yamada
• Journal: Journal of pharmacological sciences (J Pharmacol Sci) Vol. 93 Issue 4 Pg. 446-50 (Dec 2003) ISSN: 1347-8613 [Print] Japan
• PMID: 14737015 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Anxiety Agents
• Blood Glucose
• Insulin
• Serotonin Receptor Agonists
• 1-(2-pyrimidinyl)piperazine
• Glucose
• Buspirone

Topics

• Animals
• Anti-Anxiety Agents (metabolism, pharmacology)
• Blood Glucose (drug effects)
• Buspirone (analogs & derivatives, metabolism, pharmacology)
• Fasting
• Glucose
• Hyperglycemia (blood, chemically induced, prevention & control)
• Hyperinsulinism (prevention & control)
• Injections, Subcutaneous
• Insulin (blood, metabolism)
• Insulin Secretion
• Male
• Mice
• Serotonin Receptor Agonists (metabolism, pharmacology)
• Time Factors